Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 16, 2020 07:30 ET | Source: BioNTech SE; Neon Therapeutics, Inc.

BioNTech to acquire Neon to strengthen global leadership position in T cell therapies

Further expands BioNTech’s growing CAR-T and TCR therapy pipeline through addition of neoantigen specific cell therapies, including a T cell therapy targeting shared RAS oncogenesAccelerates...
January 13, 2020 07:45 ET | Source: BioNTech SE

BioNTech stärkt globale Wachstumsstrategie und beruft Ryan Richardson als Chief Strategy Officer in den Vorstand

MAINZ, Deutschland, Jan. 13, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ: BNTX, „BioNTech“ oder „das Unternehmen“) gab heute bekannt, dass der Aufsichtsrat Ryan Richardson als Chief Strategy...
January 13, 2020 07:45 ET | Source: BioNTech SE

BioNTech Appoints Ryan Richardson as Chief Strategy Officer to Support its Continued Global Expansion

MAINZ, Germany, Jan. 13, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ: BNTX, “BioNTech” or “the Company”), announced today that the Supervisory Board has appointed Ryan Richardson to the Management...
January 02, 2020 16:15 ET | Source: BioNTech SE

Präklinische Daten für neuartigen CAR-T-Zelltherapieansatz in soliden Tumoren in Science veröffentlicht

Veröffentlichung von präklinischen Proof-of-Concept-Daten für BNT211 benennt Claudin 6 (CLDN6) als neue CAR-T-Zelltherapie-Zielstruktur in soliden Tumoren und stellt neuen CARVac-Ansatz vor, ein...
January 02, 2020 16:15 ET | Source: BioNTech SE

BioNTech Announces Publication of Preclinical Data for First-in-Kind CAR-T Cell Therapy Approach Targeting Solid Tumors in Science

Publication of preclinical proof-of-concept data for BNT211 reports Claudin 6 (CLDN6) as a novel target for CAR-T cell therapy of solid tumors and introduces CARVac, a first-in-kind RNA vaccine...
December 18, 2019 09:30 ET | Source: BioNTech SE

BioNTech präsentiert auf der 38. Annual J.P. Morgan Healthcare Conference

MAINZ, Deutschland, Dec. 18, 2019 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX) gab heute bekannt, dass CEO und Mitbegründer Prof. Dr. Ugur Sahin die Firma auf der 38. Annual J.P. Morgan Healthcare...
December 18, 2019 09:30 ET | Source: BioNTech SE

BioNTech to Present at the 38th Annual J.P. Morgan Healthcare Conference

MAINZ, Germany, Dec. 18, 2019 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ: BNTX) today announced that CEO and Co-founder Ugur Sahin, MD, will present at the 38th Annual J.P. Morgan Healthcare Conference...
December 17, 2019 07:00 ET | Source: BioNTech SE

European Investment Bank provides funding of €50 million to BioNTech as part of the Investment Plan for Europe

Funds will support BioNTech’s research and development of cancer treatmentsFinancing by EU bank is provided under Investment Plan for Europe, or Juncker Plan LUXEMBOURG and MAINZ, Germany, Dec. 17,...
December 17, 2019 07:00 ET | Source: BioNTech SE

Europäische Investmentbank gewährt BioNTech 50 Millionen Euro-Finanzierung im Rahmen der Investmentoffensive für Europa

Gelder unterstützen BioNTechs Forschung und Entwicklung zur KrebsbehandlungFinanzierung wird im Rahmen der Investitionsoffensive für Europa, oder Juncker-Plan, zur Verfügung gestellt LUXEMBOURG und...
November 14, 2019 07:30 ET | Source: BioNTech SE

BioNTech SE Provides Update on Corporate Progress and Third Quarter 2019 Financial Results

Successfully transferred IND for BNT321 to BioNTech. All necessary safety and other reports and an updated protocol filed with the FDA. Phase 1/2 trial of BNT321 expected to be re-initiated in the...